Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib + Gemcitabine + Cisplatin in Urothelial Carcinoma
NCT00714948Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2008
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in urothelial carcinoma (UC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2008; status: terminated.
02
Drugs
sorafenib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00714948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00714948.